Antifungal prophylaxis with micafungin in patients treated for childhood cancer

Invasive fungal infections (IFIs) remain a major cause of infectious morality in neutropenic patients receiving chemotherapy or hematopoietic stem cell transplantation (HSCT). Micafungin exhibits broad antifungal activity against both Aspergillus and Candida species. We performed a retrospective study to determine the efficacy and safety of prophylactic micafungin against IFI in pediatric neutropenic patients during chemotherapy or HSCT.

[1]  T. Mikawa,et al.  Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. , 2009, Medical mycology.

[2]  A. Kalkancı,et al.  Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis , 2009, Pediatric blood & cancer.

[3]  N. Funata,et al.  Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Kontoyiannis,et al.  The changing epidemiology of invasive candidiasis , 2008, Cancer.

[6]  E. Thiel,et al.  Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Calandra,et al.  1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Cairo,et al.  Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation , 2008, Pediatric blood & cancer.

[9]  M. Pfaller,et al.  In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance , 2007, Journal of Clinical Microbiology.

[10]  D. Pittet,et al.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial , 2007, The Lancet.

[11]  K. Welte,et al.  Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: A pilot study for evaluation of safety and efficacy , 2007, Pediatric transplantation.

[12]  L. Danziger,et al.  Micafungin: A New Echinocandin Antifungal , 2007, Pharmacotherapy.

[13]  K. Garey,et al.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Masami Takeuchi,et al.  Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Adler-Moore,et al.  Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin , 2005, Antimicrobial Agents and Chemotherapy.

[16]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  B. Alexander,et al.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  A. Shad,et al.  Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients , 2005, Antimicrobial Agents and Chemotherapy.

[19]  M. Bermúdez,et al.  Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. , 2005, Journal of pediatric hematology/oncology.

[20]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  E. Estey,et al.  β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .

[22]  T. Sorrell,et al.  Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections , 2004, Internal medicine journal.

[23]  D. Denning.  Echinocandin antifungal drugs , 2003, The Lancet.

[24]  J. Graybill,et al.  Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. , 2003, The Journal of antimicrobial chemotherapy.

[25]  D. Stevens,et al.  Efficacy of Micafungin Alone or in Combination against Systemic Murine Aspergillosis , 2003, Antimicrobial Agents and Chemotherapy.

[26]  J. Wingard.  Antifungal chemoprophylaxis after blood and marrow transplantation. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Bergerat,et al.  Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Trupl,et al.  Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. , 1993, Chemotherapy.

[29]  M. Asaka,et al.  Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation , 2008, International journal of hematology.

[30]  Y. Kakinoki,et al.  Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. , 2007, Internal medicine.

[31]  T. Naoe,et al.  Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. , 2006, Internal medicine.

[32]  E. Estey,et al.  Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.